C-reactive protein as a prognostic marker FOR mCRPC.
Publication
, Journal Article
Abern, MR; Allott, EH; Freedland, SJ
Published in: BJU Int
December 2012
Duke Scholars
Published In
BJU Int
DOI
EISSN
1464-410X
Publication Date
December 2012
Volume
110
Issue
11 Pt B
Start / End Page
E469
Location
England
Related Subject Headings
- Urology & Nephrology
- Taxoids
- Prostatic Neoplasms
- Orchiectomy
- Male
- Humans
- Docetaxel
- C-Reactive Protein
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Abern, M. R., Allott, E. H., & Freedland, S. J. (2012). C-reactive protein as a prognostic marker FOR mCRPC. BJU Int, 110(11 Pt B), E469. https://doi.org/10.1111/j.1464-410X.2012.11156.x
Abern, Michael R., Emma H. Allott, and Stephen J. Freedland. “C-reactive protein as a prognostic marker FOR mCRPC.” BJU Int 110, no. 11 Pt B (December 2012): E469. https://doi.org/10.1111/j.1464-410X.2012.11156.x.
Abern MR, Allott EH, Freedland SJ. C-reactive protein as a prognostic marker FOR mCRPC. BJU Int. 2012 Dec;110(11 Pt B):E469.
Abern, Michael R., et al. “C-reactive protein as a prognostic marker FOR mCRPC.” BJU Int, vol. 110, no. 11 Pt B, Dec. 2012, p. E469. Pubmed, doi:10.1111/j.1464-410X.2012.11156.x.
Abern MR, Allott EH, Freedland SJ. C-reactive protein as a prognostic marker FOR mCRPC. BJU Int. 2012 Dec;110(11 Pt B):E469.
Published In
BJU Int
DOI
EISSN
1464-410X
Publication Date
December 2012
Volume
110
Issue
11 Pt B
Start / End Page
E469
Location
England
Related Subject Headings
- Urology & Nephrology
- Taxoids
- Prostatic Neoplasms
- Orchiectomy
- Male
- Humans
- Docetaxel
- C-Reactive Protein
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences